Market Report, "India Pharmaceuticals & Healthcare Report Q4 2010", published

Oct. 16, 2010 - PRLog -- India's pharmaceutical market is highly dynamic and presents significant upsides for both local firms and foreign multinationals. However, as with all emerging markets, there are under-appreciated risks to investments. BMI forecasts that combined sales of prescription drugs and over-the-counter (OTC) medicines will increase from US$15.7bn in 2009 to US$54.2bn in 2019 - a compound annual growth rate of 13.2%.

In our Q410 Business Environment Ratings, India has maintained its status as the eigth most attractive pharmaceutical market in Asia Pacific, ahead of Malaysia but behind Hong Kong. However, India's score has declined from 55.9 in Q310 to 55.3 this quarter. This was due to the Country Risks score dropping from 53 to 50. India scores above the regional average for Industry Rewards (60 versus 49) and Industry Risks (60 versus 55).

Takeovers of local firms by multinational drugmakers are becoming more frequent, rasing concerns among lawmakers and regulators. In September 2010, US-based Abbott Laboratories concluded the acquisition of the healthcare solutions business of Indian healthcare company Piramal Healthcare. Abbott Chairman and CEO Miles D. White said that the acquisition will allow Abbott to become a leading player in the Indian pharmaceutical market as well as enhancing its presence in the emerging markets. Abbott expects its sales in India to exceed US$2.5bn by 2020.

In line with BMI's core view that drugmakers based in emerging markets will increasingly produce hardto- manufacture pharmaceuticals, Mumbai-based Bhabha Atomic Research Centre (BARC) has developed three radiopharmaceuticals - lutetium-177 (Lu-177), yittrium-90 (Y-90) and phosphorous-32 (P-32) - for the treatment of cancers and other medical conditions.

The much heralded Jan Aushadi programme - which seeks to provide low-cost generic drugs to those on low-incomes - is struggling to make an impact. As of August 2010, only 46 out of a planned 300 stores had opened since 2008. The slow pace of the programme was blamed on a lack of support from the Department of Pharmaceuticals. Later that month it was revelead that plans to source unbranded generic drugs from small- and medium-sized firms for Jan Aushadhi outlets had been dropped.

In order to control the threat of fake drugs and protect the pharmaceuticals sector's brand image, the Indian government is planning to introduce a unique identification system for pharmaceutical exports. The new system will ensure that an exported drug from India is manufactured in the country and is not counterfeit. The new system is expected to be launched by November 2010.

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/87940_india_pharmaceuticals_he...

Report Table of Contents:

Executive Summary
SWOT Analysis
- India Pharmaceutical Industry SWOT
- India Political SWOT
- India Economic SWOT
- India Business Environment SWOT
- Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q410
- Rewards
- Risks
India - Market Summary
Regulatory Environment
- Table: Responsibilities Of India's Department Of Pharmaceuticals
- Pharmaceutical Advertising
- Pharmacovigilance
- IP Regime
- Table: History Of The Indian Patent System
- Patent Disputes
- Counterfeit Medicines
- Pricing And Reimbursement
Industry Trends And Developments
- Epidemiology
- Healthcare Sector
- Healthcare Funding
- Healthcare Insurance
- Research And Development
- Clinical Trials
- Recent Developments In The Clinical Trials Industry
- Active Pharmaceutical Ingredients
- Biotechnology Sector
- Traditional Medicines
Industry Forecast Scenario
- Overall Market Forecast
- Key Growth Factors - Industry
- Key Growth Factors - Macroeconomic
- Table: India - Economic Activity
- Prescription Drug Market Forecast
- Patented Drug Market Forecast
- Generic Drug Market Forecast
- OTC Medicine Market Forecast
- Pharmaceutical Trade Forecast
- Medical Device Market Forecast
- Other Healthcare Data Forecasts
- Key Risks To BMI's Forecast Scenario
Competitive Landscape
- Top 30 Pharmaceutical Companies In India According To Moving Average Total (MAT) Sales To July 2010 (US$mn)
- Key Pharmaceutical Industry Developments
Company Profiles
- Leading Indigenous Manufacturers
- Ranbaxy Laboratories
- Cipla
- Dr Reddy's Laboratories
- Aurobindo Pharmaceutical
- Venus Remedies
- Granules India
- Piramal Healthcare
- Zydus Cadila
- Leading Multinational Manufacturers
- Pfizer
- GlaxoSmithKline (GSK)
- Novartis
- Sanofi-Aventis
- Merck & Co
Country Snapshot: India Demographic Data
- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Section 2: Education and Healthcare
- Table: Education, 2002-2005
- Table: Vital Statistics, 2005-2030
- Section 3: Labour Market And Spending Power
- Table: Employment Indicators, 1996-2001
- Table: Consumer Expenditure, 2000-2012 (US$)
- Table: Average Annual Manufacturing Wages, 2000-2012
BMI Methodology
- How We Generate Our Pharmaceutical Industry Forecasts
- Pharmaceuticals Business Environment Ratings
- Risk/Reward Ratings Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components
- Sources
Forecast Tables

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.